Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey

dc.date.accessioned	2023-03-06T07:32:26Z
dc.date.available	2023-03-06T07:32:26Z
dc.date.issued	2023
dc.identifier.citation	Ann Hematol. 2023 Jan;102(1):133-140. doi: 10.1007/s00277-022-05052-x. Epub 2022 Nov 19.
dc.identifier.uri	https://hdl.handle.net/20.500.12619/100317
dc.relation.isversionof	10.1007/s00277-022-05052-x
dc.relation.isversionof	10.1007/s00277-022-05052-x
dc.title	Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey
dc.relation.journal	Ann Hematol
dc.identifier.doi	10.1007/s00277-022-05052-x
dc.contributor.author	Dal MS
dc.contributor.author	Dal MS
dc.contributor.author	Ulu BU
dc.contributor.author	Uzay A
dc.contributor.author	Akay OM
dc.contributor.author	Beşışık S
dc.contributor.author	Yenerel MN
dc.contributor.author	Çelik S